The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tiziana plans switch to US; Vertu ups guidance

Fri, 20th Aug 2021 11:13

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Remote Monitored Systems PLC, up 25% at 0.75 pence, 12-month range 0.36p-5.00p. Reports new Anglo-Indian partnership between its subsidiary Pharm 2 Farm Ltd and India's VKE Enterprises to distribute its Pro-Larva mask. The London-based survey and inspection services provider says Pro-Larva mask is the first anti-viral mask to be approved by the UK Medicines & Healthcare Products Regulatory Agency as a class 1 medical device. The Pro-Larva face mask is made in Britain using patented a-Virion nanotechnology that is clinically proved to kill 99.9% of Covid and Influenza viruses, within 5 minutes of contact, and continues to kill the virus for seven hours, RMS says.

----------

Vertu Motors PLC, up 7.6% at 50.80 pence, 12-month range 24.40p-50.60p. Sees strong used vehicle gross margin retention, due to "exceptional" UK used car market conditions. As a result, expects adjusted pretax profit of no less than GBP50 million in year to August 31, upped from previous guidance between GBP40 million to GBP45 million. "The group's like-for-like new vehicle order take for the key month of September is currently running in excess of prior year levels, however, there is a risk that well documented new vehicle supply shortages will result in vehicle deliveries being delayed into future periods. As a consequence of reduced new vehicle supply, used vehicle supply may also be restricted in the coming months," company adds.

----------

AIM - LOSERS

----------

Amur Minerals Corp, down 11% at 2.18 pence, 12-month range 1.30p-2.90p. Notes permanent conditions report on its far east Russia Kun-Manie nickel copper sulfide project completed. It shows the nickel cutoff grade is calculated to be 0.3% nickel. Revenue is based on a presently conservative nickel price of USD13,300 per tonne and a copper price of USD5,960 per tonne. Metal recoveries are anticipated to be 74% for nickel and 52% for copper. Mine ore production and the nominal mill throughput at six million tonnes per annum indicates a potential mine life in the order of 25 years. The report says the reserve base is substantial and suitable to potentially sustain an 11.2 million tonne per year throughput

----------

Tiziana Life Sciences PLC, down 12% at 51.08 pence, 12-month range 51.08p-204.00p. Formally starts strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, as the ultimate parent company of the Tiziana group. Shares will be swapped for shares in the new parent company, which will then be listed in the US on Nasdaq. As a result, Tiziana to be delisted in London. "The interests of its business and shareholders are best served by aligning the place of the listing with the principal business activities of the Tiziana group, which are predominately based in the US," company explains.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Dec 2019 15:38

Tiziana initiates study of 'Foralumab' in coated capsule form

(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.

Read more
4 Dec 2019 11:52

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Read more
20 Nov 2019 13:02

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Read more
1 Nov 2019 17:31

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Read more
30 Sep 2019 10:27

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Read more
16 Sep 2019 13:03

Tiziana Life Sciences Gets New Foralumab Formulation US Trial Approval

(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in

Read more
10 Sep 2019 14:34

Tiziana Life Sciences Announces Positive Data From Foralumab Trial

(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a

Read more
4 Sep 2019 11:04

Encouraging Data From Tiziana Life Sciences Milciclib Cancer Study

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in

Read more
22 Jul 2019 09:54

Tiziana Reports No Drug-Related Deaths In Milciclib Liver Cancer trial

(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6

Read more
1 Jul 2019 10:49

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith,

Read more
1 Jul 2019 10:20

Tiziana Notes Positive Study Of Drug Similar To Foralumab In Diabetes

(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company

Read more
1 May 2019 10:08

FDA asks Tiziana for more information on next 'foralumab' trial

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.

Read more
24 Apr 2019 12:20

Most Patients Stick With Milciclib In Tiziana Life Sciences Study

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were -

Read more
4 Apr 2019 10:58

Tiziana Life Sciences Annual Loss Narrows On Marginally Reduced Costs

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted

Read more
20 Mar 2019 13:01

Tiziana Life Sciences Submits Application For Foralumab Trial In US

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it has submitted an application in the US to begin a phase one trial of its autoimmune and inflammatory disease drug new drug a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.